header logo image


Page 29«..1020..28293031..4050..»

Archive for the ‘Regenerative Medicine’ Category

Regenerative Medicine Adoption of Innovative Offerings and Forecast 2019-2026 – Melanian News

Tuesday, January 21st, 2020

Global Liver Biopsy System Market Research Report 2019-2025 states that the Liver Biopsy System market has been raising and impacting the international economy in terms of growth rate, revenue, sale, market share, and size. The global market has been over-looking changes in its industry. The report provides the reader with a study fundamental attributes of the industry covering lucrative business strategies, market demands, leading players of the market, and futuristic perspective through various angles for 2019 to 2025 forecast time period. It covers the current situations of the market to represent an outlook of the market to businesses to boost their profitable strategies. The report offers an expert review and detail investigation of fragments of the market using which clients can use for their business favorable position

The market report figures out the growth patterns of organization, areas and type or application from 2019 to 2025. It throws light on the most trending facts of the Liver Biopsy System market, most prominent market, the maximum revenue, manufacture analysis, market share, market size, market forecast trends, market sales, production, supply, and demand. Prominent players are evaluated on the basis of their gross margin, price, sales, revenue, business, products, and other company details.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketresearchplace.com/report-detail/182828/request-sample

The well-established players in the market along with capacity, production, ex-factory price, revenue and market share are covered including: BD, Boston Scientific, Cook Medical, Argon Medical Devices, RI.MOS, Sterylab, Veran Medical, Medtronic, INRAD Inc,

The key regions are extensively analyzed with respect to every parameter of the geographies in question, comprising, North America (United States, Canada, Mexico), Europe (Germany, France, UK, Italy, Russia), Asia-Pacific (China, Japan, South Korea, India, Australia, Indonesia, Thailand, Malaysia, Philippines, Vietnam), Central & South America (Brazil), Middle East & Africa (Turkey, GCC Countries, Egypt, South Africa).

Market segment by type, the product can be split into Percutaneous, Transjugular, Laparoscopic, Transgastric,

Market segment by application, split into: Hospitals, Clinics, Diagnostic Labs, Other,

Drivers & Hindrances of the Liver Biopsy System market: How does the report explicate on the same:

ACCESS FULL REPORT: https://www.marketresearchplace.com/report/global-liver-biopsy-system-market-research-report-2019-2025-182828.html

Moreover The Report Offer:

The report covers an overview of revenue, demand, and supply of data, futuristic cost, and growth analysis during the projected year. In a represented strategy, the authors have used, the correct figures and the graphical depiction. The report states that capabilities and development have boosted the number of huge business models and organizations across the globe. Additionally, comprehensive data about the product consumption across different sections as well as the valuation developed by these regions is also explained in the Liver Biopsy System market report.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

See original here:
Regenerative Medicine Adoption of Innovative Offerings and Forecast 2019-2026 - Melanian News

Read More...

Zika Virus’ Key into Brain Cells ID’d, Leveraged to Block Infection and Kill Cancer Cells – UC San Diego Health

Tuesday, January 21st, 2020

Zika virus infection can stunt neonatal brain development, a condition known as microcephaly, in which babies are born with abnormally small heads. To determine how best to prevent and treat the viral infection, scientists first need to understand how the pathogen gets inside brain cells.

Employing different approaches to answer different questions, two research teams at University of California San Diego School of Medicine independently identified the same molecule v5 integrin as Zika virus key to entering brain stem cells.

In a pair of papers published January 16, 2020 by Cell Press, the researchers also found ways to take advantage of the integrin to both block Zika virus from infecting cells and turn it into something good: a way to shrink brain cancer stem cells.

Integrins are molecules embedded in cell surfaces. They play important roles in cell adherence and communication, and are known to be involved in cancer progression and metastasis. Several other integrins are known entry points for other viruses, including adenovirus, foot-and-mouth disease virus and rotavirus, but v5 was not previously known for its role in viral infections.

One team, led by Tariq Rana, PhD, professor and chief of the Division of Genetics in the Department of Pediatrics at UC San Diego School of Medicine and Moores Cancer Center, used CRISPR gene editing to systematically delete every gene in a 3D culture of human glioblastoma (brain cancer) stem cells growing in a laboratory dish. Then they exposed each variation to Zika virus to determine which genes, and the proteins they encode, are required for the virus to enter the cells. The virus was for the first time labeled with green fluorescent protein (GFP) to allow the researchers to visualize viral entry into the cells.

3D human brain organoids. Left: normal, uninfected. Center: infected with Zika virus. Right: infected with Zika virus and treated with cilengitide, which protects the cells from destruction by the virus.

Their study, published in Cell Reports, uncovered 92 specific human brain cancer stem cell genes that Zika virus requires to infect and replicate in the cells. But one gene stood out, the one that encodes v5 integrin.

Integrins are well known as molecules that many different viruses use as doorknobs to gain entry into human cells, Rana said. I was expecting to find Zika using multiple integrins, or other cell surface molecules also used by other viruses. But instead we found Zika uses v5, which is unique. When we further examined v5 expression in brain, it made perfect sense because v5 is the only integrin member enriched in neural stem cells, which Zika preferentially infects. Therefore, we believe that v5 is the key contributor to Zikas ability to infect brain cells.

The second study, published in Cell Stem Cell, was led by Jeremy Rich, MD, professor in the Department of Medicine at UC San Diego School of Medicine and director of neuro-oncology and of the Brain Tumor Institute at UC San Diego Health. Knowing that many viruses use integrins for entry into human cells, Richs team inhibited each integrin with a different antibody to see which would have the greatest effect.

When we blocked other integrins, there was no difference. You might as well be putting water on a cell, said Rich, who is also a faculty member in the Sanford Consortium for Regenerative Medicine and Sanford Stem Cell Clinical Center at UC San Diego Health. But with v5, blocking it with an antibody almost completely blocked the ability of the virus to infect brain cancer stem cells and normal brain stem cells.

Richs team followed up by inhibiting v5 in a glioblastoma mouse model with either an antibody or by deactivating the gene that encodes it. Both approaches blocked Zika virus infection and allowed the treated mice to live longer than untreated mice. They also found that blocking the v5 integrin in glioblastoma tumor samples removed from patients during surgery blocked Zika virus infection.

Ranas team also blocked v5 in mice, treating them daily with cilengitide or SB273005, two experimental cancer drugs that target the integrin. Six days after Zika virus infection, the brains of their drug-treated mice contained half as much virus as mock-treated mice.

The neat thing is that these findings not only help advance the Zika virus research field, but also opens the possibility that we could similarly block the entry of multiple viruses that use other integrins with antibodies or small molecule inhibitors, Rana said.

Rana and team are now engineering a mouse model that lacks v5 integrin in the brain a tool that would allow them to definitively prove the molecule is necessary for Zika viral entry and replication.

Rich is a neuro-oncologist who specializes in diagnosing and treating patients with glioblastoma, a particularly aggressive and deadly type of brain tumor. When he first saw how the Zika virus shrinks brain tissue, it reminded him of what he hopes to achieve when hes treating a patient with glioblastoma. In 2017, he and collaborators published a study in which they determined that Zika virus selectively targets and kills glioblastoma stem cells, which tend to be resistant to standard treatments and are a big reason why glioblastomas recur after surgery and result in shorter patient survival rates.

Richs latest study helps account for the virus preference for glioblastoma stem cells over healthy brain cells. The v5 integrin is made up of two separate subunits v and 5. The team found that glioblastoma stem cells produce a lot of both the v subunit (associated with stem cells) and 5 subunit (associated with cancer cells). Together, these units form the v5 integrin, which, the team discovered, plays an important role in glioblastoma stem cell survival. Those high levels of v5 integrin also help explain why, in the study, glioblastoma stem cells were killed by Zika virus at much higher rates than normal stem cells or other brain cell types.

It turns out that the very thing that helps cancer cells become aggressive cancer stem cells is the same thing Zika virus uses to infect our cells, Rich said.

To see how this might play out in a more realistic model of human disease, Richs team partnered with an expert in human brain disease modeling Alysson Muotri, PhD, professor at UC San Diego School of Medicine, director of the UC San Diego Stem Cell Program and a member of the Sanford Consortium for Regenerative Medicine, and team. Pinar Mesci, PhD, a postdoctoral researcher in Muotris lab, generated a new brain tumor model, where human glioblastoma tumors were transplanted into human brain organoids, laboratory mini-brains that can be used for drug discovery. The researchers discovered that Zika virus selectively eliminates glioblastoma stem cells from the brain organoids. Inhibiting v5 integrin reversed that anti-cancer activity, further underscoring the molecules crucial role in Zika virus ability to destroy cells.

Now Richs team is partnering with other research groups to perform targeted drug studies. In addition to searching for drugs to block Zika virus, as Ranas group is doing, Rich is interested in genetic modifications to the virus that could help better target its destruction to brain cancer cells, while leaving healthy cells alone.

While we would likely need to modify the normal Zika virus to make it safer to treat brain tumors, we may also be able to take advantage of the mechanisms the virus uses to destroy cells to improve the way we treat glioblastoma, Rich said. We should pay attention to viruses. They have evolved over many years to be very good at targeting and entering specific cells in the body.

Zika virus was perhaps best known in 2015-16, when a large outbreak affected primarily Latin America, but also several other regions of the world. While that particular epidemic has passed, Zika virus has not gone away. Smaller, local outbreaks continue and this past summer, the first few cases of native Zika virus infection were recorded in Europe. Scientists warn Zika could continue to spread as climate change affects the habitat range of the mosquito that carries it. The virus can also be transmitted from pregnant mother to fetus, and via sexual contact. More than half of all people on Earth are at risk for Zika virus infection, and there is no safe and effective treatment or vaccine.

Co-authors of Ranas study, published January 16, 2020 in Cell Reports, include: Shaobo Wang, Qiong Zhang, Shashi Kant Tiwari, Gianluigi Lichinchi, Edwin H. Yau, Hui Hui, Wanyu Li, UC San Diego; and Frank Furnari, UC San Diego and Ludwig Institute for Cancer Research.

This research was funded, in part, by the National Institutes of Health (grants AI125103, CA177322, DA039562, DA046171 and DA049524).

Co-authors of Richs study, published January 16, 2020 in Cell Stem Cell, also include: Zhe Zhu, Jean A. Bernatchez, Xiuxing Wang, Hiromi I. Wettersten, Sungjun Beck, Alex E. Clark, Qiulian Wu, Sara M. Weis, Priscilla D. Negraes, Cleber A. Trujillo, Jair L. Siqueira-Neto, David A. Cheresh, UC San Diego; Ryan C. Gimple, Leo J.Y. Kim, UC San Diego and Case Western Reserve University; Simon T. Schafer, Fred H. Gage, Salk Institute for Biological Studies; Briana C. Prager, UC San Diego, Case Western Reserve University and Cleveland Clinic; Rekha Dhanwani, Sonia Sharma, La Jolla Institute for Allergy and Immunology; Alexandra Garancher, Robert J. Wechsler-Reya, Sanford Burnham Prebys Medical Discovery Institute; Stephen C. Mack, Baylor College of Medicine, Texas Childrens Hospital; Luiz O. Penalva, Childrens Cancer Research Institute; Jing Feng, Zhou Lan, Rong Zhang, Alex W. Wessel, Michael S. Diamond, Hongzhen Hu, Washington University School of Medicine; Sanjay Dhawan, and Clark C. Chen, University of Minnesota.

The research was funded, in part, by the National Institutes of Health (grants CA217065, CA217066, CA203101, CA159859, CA199376, NS097649-01, CA240953-01, NS096368, R01DK103901,R01AA027065, MH107367, N5105969, CA045726, CA050286, CA197718, CA154130, CA169117, CA171652, NS087913, NS089272), California Institute for Regenerative Medicine (CIRM, grants FA1-00607, DISC209649) and International Rett Syndrome Foundation.

Disclosures: Tariq Rana is a co-founder of, member of the scientific advisory board for, and has equity interest in ViRx Pharmaceuticals. Alysson Muotri is a co-founder and has equity interest in TISMOO, a company dedicated to genetic analysis focusing on therapeutic applications customized for autism spectrum disorder and other neurological disorders. David Cheresh is a co-founder of TargeGen and AlphaBeta Therapeutics, a new but currently unfunded company developing an antibody to integrin v5 involved in cancer treatment. The terms of these arrangements have been reviewed and approved by UC San Diego in accordance with its conflict of interest policies. In addition, Michael Diamond, of Washington University School of Medicine, is a consultant for Inbios and Atreca and serves on the Scientific Advisory Board of Moderna.

Follow this link:
Zika Virus' Key into Brain Cells ID'd, Leveraged to Block Infection and Kill Cancer Cells - UC San Diego Health

Read More...

Contract Research Organization (CRO) Market Outlook to 2024 – Increased Technology Adoption in the Form of eClinical Solutions & Innovative Trial…

Tuesday, January 21st, 2020

DUBLIN, Jan. 20, 2020 /PRNewswire/ -- The "Global Contract Research Organization (CRO) Market, Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

Owing to a constantly changing pharmaceutical landscape, the industry is expected to witness a moderate 4% to 5% growth in the next 5 to 7 years, to surpass $1.5 trillion by 2025.

Increased technology adoption in the form of eClinical solutions and innovative trial designs is expected to transform the CRO landscape.

In coordination with the industry growth, market participants are investing about 8% to 10% of their revenues toward drug discovery and development. With an overall R&D investment of approximately $170 billion in 2018, the industry is working toward developing new and innovative curative therapies (e.g., regenerative medicine).

As a result of a higher R&D activity, there is higher reliance on outsourcing partners (e.g., CRO vendors) that support pharma and biotech participants with cost-effective and time-efficient drug development services. The global CRO industry is a highly fragmented and competitive market, with more than 1,000 participants globally.

Europe is emerging as a key location for clinical research, with several small-to-mid segment niche CROs focusing on the region and, hence, propelling growth. Moreover, with APAC providing cheaper but effective alternatives for drug development, several big pharma companies are collaborating with participants in the region, thereby, making it the strongest growing region across the CRO industry.

A highly fragmented market is a result of numerous small-to-mid segment participants focused on either a specific therapy area or specific service segment. This, in turn, is propelling consolidation in the industry, with leading CROs acquiring these niche participants, thus, increasing their service portfolio and geographic span.

The global CRO market is also witnessing an increased adoption of digitization in the form of eClinical solutions, using AI and machine learning-based platforms, providing an opportunity for several CROs to position themselves in the segment. Several technology-focused CROs are now developing in-house expertise which is changing the global clinical trial paradigm with the implementation of adaptive, virtual, and remote clinical trials. The companies are also moving toward an embedded business model by integrating their services with that of the sponsor's business strategy, thereby, supporting as an end-to-end solution provider.

Key Issues Addressed

Key Topics Covered

1. Executive Summary

2. Total CRO Market - Overview

3. Drivers, Restraints, and Trends - Total CRO Market

4. Total CRO Market - Forecasts and Trends

5. Discovery and Preclinical CRO Market Analysis

6. Clinical CRO Market Analysis

7. Regional Forecast Analysis - North America

8. Regional Forecast Analysis - Europe

9. Regional Forecast Analysis - Asia-Pacific

10. Regional Forecast Analysis - Rest of World

11. Total CRO Market - Competitive Environment

12. Clinical CRO Subsegment Analysis

13. Bioanalytical and cGMP Testing Subsegment

14. Subsegment Analysis - Central Laboratory Services

15. Subsegment Analysis - Biostatistics

16. Subsegment Analysis - Data Management

17. Subsegment Analysis - Pharmacovigilance

Story continues

18. Subsegment Analysis - Health Economics Outcomes Research (HEOR)

19. Digital Disruption in the CRO Industry

20. Visioning Scenarios

21. CRO Industry Stakeholder Landscape

22. The Last Word

For more information about this report visit https://www.researchandmarkets.com/r/frjl4a

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/contract-research-organization-cro-market-outlook-to-2024---increased-technology-adoption-in-the-form-of-eclinical-solutions--innovative-trial-designs-expected-to-transform-the-cro-landscape-300989712.html

SOURCE Research and Markets

View post:
Contract Research Organization (CRO) Market Outlook to 2024 - Increased Technology Adoption in the Form of eClinical Solutions & Innovative Trial...

Read More...

Those Who Purchased China Regenerative Medicine International (HKG:8158) Shares Three Years Ago Have A 95% Loss To Show For It – Simply Wall St

Tuesday, January 21st, 2020

It is a pleasure to report that the China Regenerative Medicine International Limited (HKG:8158) is up 129% in the last quarter. But that is meagre solace in the face of the shocking decline over three years. The share price has sunk like a leaky ship, down 95% in that time. So it sure is nice to see a big of an improvement. But the more important question is whether the underlying business can justify a higher price still.

We really feel for shareholders in this scenario. Its a good reminder of the importance of diversification, and its worth keeping in mind theres more to life than money, anyway.

View our latest analysis for China Regenerative Medicine International

Because China Regenerative Medicine International made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. Thats because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

Over the last three years, China Regenerative Medicine Internationals revenue dropped 26% per year. Thats definitely a weaker result than most pre-profit companies report. And as you might expect the share price has been weak too, dropping at a rate of 64% per year. Never forget that loss making companies with falling revenue can and do cause losses for everyday investors. Its worth remembering that investors call buying a steeply falling share price catching a falling knife because it is a dangerous pass time.

The companys revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

Its good to see that there was some significant insider buying in the last three months. Thats a positive. On the other hand, we think the revenue and earnings trends are much more meaningful measures of the business. Dive deeper into the earnings by checking this interactive graph of China Regenerative Medicine Internationals earnings, revenue and cash flow.

China Regenerative Medicine International shareholders are down 81% for the year, but the market itself is up 9.4%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last years performance may indicate unresolved challenges, given that it was worse than the annualised loss of 45% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Like risks, for instance. Every company has them, and weve spotted 5 warning signs for China Regenerative Medicine International (of which 1 shouldnt be ignored!) you should know about.

China Regenerative Medicine International is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on HK exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Read more from the original source:
Those Who Purchased China Regenerative Medicine International (HKG:8158) Shares Three Years Ago Have A 95% Loss To Show For It - Simply Wall St

Read More...

UK biotech PhoreMost to work with Otsuka on gene therapy projects – – pharmaphorum

Tuesday, January 21st, 2020

Building on an R&D tie-up with an Indian stem cell institution last year, UK biotech PhoreMost has begun a collaboration with Japans Otsuka working on several gene therapy projects.

Cambridge-based PhoreMost said it will use its next-generation phenotypic screening platform Siteseeker to identify novel targets for Otsukas therapeutics discovery programmes.

Novel targets identified will be further validated and characterised by Otsuka as part of its internal development pipeline, with an initial focus on gene therapy applications of identified targets.

Siteseeker looks at different protein shapes to find functionally active peptides that can be targeted by new therapies.

The technology looks at the entire proteome all of the proteins expressed in a live cell environment looking for druggable targets for a chosen disease.

Financial details of the agreement were not disclosed.

Dr Chris Torrance, CEO of PhoreMost, said: This collaboration with Otsuka is further recognition of the power of the Siteseeker approach to drive the identification of novel, druggable targets.

We are particularly excited to be exploring not only small molecule therapeutics but also gene therapy applications of our platform.

PhoreMost was one of two UK-based companies to receive funding from the government-backed agency Innovate UK to receive funding for small molecule research.

The 1 million funding was announced in 2018, and supported PhoreMost and the immune-oncology firm NeoPhore.

The companies won the funding as part of a competition organised by Innovate UK and funded by the UKs Biomedical Catalyst.

PhoreMost is also working with Indias Centre for Chemical Biology and Therapeutics, part of the Institute for Stem Cell Science and Regenerative Medicine (inStem).

The project began in July last year and, with funding from the Indian government, aims to create chemical tools that modulate novel classes of drug targets.

InStem is researching the genetic mechanisms of potency, differentiation and proliferation in human pluripotent cells.

It aims to examine diseases that can potentially be treated by stem cells.

See original here:
UK biotech PhoreMost to work with Otsuka on gene therapy projects - - pharmaphorum

Read More...

Regenerative Medicine Market Business Scenario 2020 | SWOT Analysis by Major Players- Organogenesis Osiris Therapeutics, Vericel Corporation, Stryker…

Tuesday, January 21st, 2020

New Jersey, United States, The report titled, Regenerative Medicine Market has been recently published by Verified Market Research.The report has offered exhaustive analysis of the Regenerative Medicine Market taking into consideration all the crucial aspects like growth factors, constraints, market developments, future prospects, and trends. Market researchers and industry experts have pointed out the key market trends and prospects that may impact the overall Regenerative Medicine Market growth. This will help players to leverage the opportunities to strengthen their position. Also, the report throws light on the important factors that are contributing to the Regenerative Medicine Market growth. Additionally, challenges and impeding factors that could hamper the growth of the Regenerative Medicine Market in the years to come are mentioned in the report.

Global Regenerative Medicine Market was valued at USD 19.10 Billion in 2018 and is expected to witness a growth of 22.72% from 2019-2026 and reach USD 98.10 Billion by 2026.

Request a Sample Copy of this report @https://www.verifiedmarketresearch.com/download-sample/?rid=7157&utm_source=FSA&utm_medium=003

Top 10 Companies in the Global Regenerative Medicine Market Research Report:

Global Regenerative Medicine Market: Competitive Landscape

Competitive landscape of a market explains strategies incorporated by key players of the market. Key developments and shift in management in the recent years by players has been explained through company profiling. This helps readers to understand the trends that will accelerate the growth of market. It also includes investment strategies, marketing strategies, and product development plans adopted by major players of the market. The market forecast will help readers make better investments.

Global Regenerative Medicine Market: Drivers and Restrains

This section of the report discusses various drivers and restrains that have shaped the global market. The detailed study of numerous drivers of the market enable readers to get a clear perspective of the market, which includes market environment, government policies, product innovations, breakthroughs, and market risks.

The research report also points out the myriad opportunities, challenges, and market barriers present in the Global Regenerative Medicine Market. The comprehensive nature of the information will help the reader determine and plan strategies to benefit from. Restrains, challenges, and market barriers also help the reader to understand how the company can prevent itself from facing downfall.

Global Regenerative Medicine Market: Segment Analysis

This section of the report includes segmentation such as application, product type, and end user. These segmentations aid in determining parts of market that will progress more than others. The segmentation analysis provides information about the key elements that are thriving the specific segments better than others. It helps readers to understand strategies to make sound investments. The Global Regenerative Medicine Market is segmented on the basis of product type, applications, and its end users.

Global Regenerative Medicine Market: Regional Analysis

This part of the report includes detailed information of the market in different regions. Each region offers different scope to the market as each region has different government policy and other factors. The regions included in the report are North America, South America, Europe, Asia Pacific, and the Middle East. Information about different region helps the reader to understand global market better.

Ask for Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7157&utm_source=FSA&utm_medium=003

Table of Content

1 Introduction of Regenerative Medicine Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Regenerative Medicine Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Regenerative Medicine Market, By Deployment Model

5.1 Overview

6 Regenerative Medicine Market, By Solution

6.1 Overview

7 Regenerative Medicine Market, By Vertical

7.1 Overview

8 Regenerative Medicine Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Regenerative Medicine Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Customization of Report @ https://www.verifiedmarketresearch.com/product/global-regenerative-medicine-market/?utm_source=FSA&utm_medium=003

Highlights of Report

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

Originally posted here:
Regenerative Medicine Market Business Scenario 2020 | SWOT Analysis by Major Players- Organogenesis Osiris Therapeutics, Vericel Corporation, Stryker...

Read More...

JPM: Biotech, VC execs on where the industry should look beyond cancer – FierceBiotech

Tuesday, January 21st, 2020

SAN FRANCISCOOncology is clearly a major medical and societal issue: a major killer that, while predominately affecting the older population, can strike the young through a mixture of environmental factors or a genetic lottery. Its no wonder we struggle to even call it by its name, preferring just the "big C."

Biopharma has acted accordingly over the years and spent billions (and made many more billions) developing new oncology therapies, with the media and political focus falling on cancer drugs far more acutely than any other area, whether that be over pricing (the current average cost of a new cancer drug in the U.S. is around $100,000), effectiveness/safety or rejection from healthcare gatekeepers, such as the National Institute for Health and Care Excellence in England.

But cancer is only one disease area: Heart disease is the biggest killer in the U.S., yet there are very few new and innovative CV drugs out there, with influenza complications, such as pneumonia, Alzheimers disease, stroke and diabetes complications all leading causes of death in the U.S. There has been a war on cancer, but not a war on stroke.

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

There is also the growing threat of antimicrobial resistance, where decades-old antibiotics are ceasing to work against common forms of bacteria as they evolve; this, coupled with the fact that most life science companies arent working on a next generation of antibiotics (R&D costs are high with little or no ROI), means we could very well be facing a new surge in deaths in the future from once preventable diseases and infections.

At the J.P. Morgan Healthcare Conference in San Francisco this week, we at FierceBiotech wondered what the industry was doing about this and asked a range of life science C-suite execs: What therapeutic areas beyond cancer are most important to the industry now? both in terms of unmet need as well as where there is some real innovation.

Jim Robinson, chief operating officer at Paragon Biosciences, said: I spent 10 years in oncology, so I understand that point. Still, the biggest issue we face today that has to be figured out is Alzheimers. Looking at the aftermath, its scaryits going to be trillions of dollars in 20 short years in terms of the expense treating patients with Alzheimers. In 20 short years, I might be one of those patients!

I think its been a vast wasteland of failure. Im hoping something comes about before Im 70 to allow us to treat it. Whether the industry is willing to shift more resources to pursue treatments or not remains to be seen, especially after the latest failures. I dont know if the industry will shift to Alzheimers or more CNS treatments associated with cognition, but Im hoping.

Oncology good news is when the industry shifted and thousands of drugs moved through development. We see a significant transformation in certain cancers. If the incentive or the approach from a regulatory pathway that shifts incentives to research in Alzheimers, we will find some answers.

The biotechs CEO, Jeff Aronin, who is also CEO of Paragon Capital Partners, echoed this need for answers. I have a focus there with one of our companies, but in general, I would answer a little broader, he explained. Ive been involved in CNS drug development for a very long time and remember the 90s, which they called the decade of the brain, but we really didnt make a lot of advances in neuroscience and psychiatry that we thought we would have.

I think over the next few years is where we are really going to see many medicines approved. We have learned so much more and advancing in many different areas. In neuroscience and psychiatry, I would add theyre also an area of tremendous cost to the healthcare system and we still dont have a lot of great solutions, whether its Alzheimers or any of the neuropsychiatry areas were working in.

BioNTechs Sean Marrett also saw Alzheimers and other neuroscience areas, such as Parkinsons disease, as still major and unmet issues, as well as multiple sclerosis, which has seen great strides but still needs work.

Alzheimers is certainly a major issue, but also one that is more entrenched in the west: We live longer and are therefore more susceptible to diseases associated with aging.

Lyndra Therapeutics CEO Patricia Hurter asked us whether we meant our question in relation to the developed world or the developing world? We asked her two cents on both.

Women in Africa either get pregnant or get HIV, she said starkly. Their economic prospects are horrendous. It means their childrens economic prospects are horrendous. Were working with Gilead on HIV prophylaxis and on an oral birth control. Eventually, when the drugs are potent enough, we could do a once-a-month pill of each. To have them in one capsulethat would be fabulous. That would be transformative for developing countries.

For America, I think so many things like hypertension and diabetes are a chronic epidemic and people are having bad health outcomes [that could be avoided] if they took well proven drugs in an adherent way. Its an adherence issue. Theyre not feeling sick so they dont take the medicine. But in fact, it is still progressing [it, referring to stuff like hypertension, NASH that progressively gets worse without you feeling sick until its advanced].

It leads to unnecessary hospitalizations. If we could combine modern methods of distribution that a poly-pill combination that a person neededonce a week they would take one thing to keep them from progressing.

Karuna Therapeutics CEO Steve Paul also pointed to suicide rates that keep going up, whereas in certain types of cancer and cardiovascular disease theyve started tracking down.

And, finally, Westlake Village Biopartners Managing Partner Sean Harper said: Because there are so many areas of unmet need, its hard to say just one therapeutic area or one modality. Its exciting: the cellular engineering thats going to result in the ability to do regenerative medicine type efforts is I think going to be the next really amazing sort of thing.

With the fact that you can manipulate human cells now the way you can, and make multiple difficult edits to engineer things out of them and so on, that is just a new frontier. There are a lot of settings where you can just imagine what that can do. Its not 100 years away. Its now. Its happening already, people are doing it. I think that, to me, is the most exciting area.

See the original post:
JPM: Biotech, VC execs on where the industry should look beyond cancer - FierceBiotech

Read More...

Global Regenerative Medicine Market expected to Growth at an impressive CAGR during the period of 2020-2025 – Fusion Science Academy

Tuesday, January 21st, 2020

This report focuses on global Vision Sensor status, future forecast, growth opportunity, key market, and key players. The study objectives are to present the Vision Sensor development in the United States, Europe, and China.

In 2018, the global Vision Sensor market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2019-2025.

The report also summarizes the various types of Vision Sensor market. Factors that influence the market growth of particular product category type and market status for it. A detailed study of the Vision Sensor Market has been done to understand the various applications of the usage and features of the product. Readers looking for scope of growth with respect to product categories can get all the desired information over here, along with supporting figures and facts.

Get Global Vision Sensor sample copy of thisreport https://www.lexisbusinessinsights.com/request-sample-75861

Top Key players: Festo, BALLUFF, BANNERENGINEERINGCORP, CARLOGAVAZZI, COGNEX, DatalogicAutomation, di-soric, HEXAGONMANUFACTURINGINTELLIGENCE, ifmelectronic, ipfelectronicgmbh, LaetusGmbH, LMITechnologies, OMRON, Optekelectronics, Pepperl+FuchsGmbH, SENSOPART, Servo-Robot, SICK, TelemecaniqueSensors, TURCK, VisionComponents, and wenglorsensoricGmbH

Vision Sensor Market: Regional Segment Analysis.

This report provides pin-point analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed based on how the Vision Sensor Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making an in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global Vision Sensor Market?

What are the key market trends impacting the growth of the Global Vision Sensor Market?

What are the challenges to market growth?

Who are the key vendors in the Global Vision Sensor Market?

What are the market opportunities and threats faced by the vendors in the Global Vision Sensor Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia Vision Sensor Market;

3.) The North American Vision Sensor Market;

4.) The European Vision Sensor Market;

5.) Market entry and investment feasibility;

6.) The reports conclusion.

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.

Vision Sensor Market report will enlist all sections and research for every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward-looking perspective on different factors driving or restraining the market growth

It provides a six-year forecast assessed based on how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making an in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Global Vision Sensor Complete Brochure @ https://www.lexisbusinessinsights.com/request-sample-75861

About Us:

Statistical surveying reports is a solitary goal for all the business, organization and nation reports. We highlight a huge archive of most recent industry reports, driving and specialty organization profiles, and market measurements discharged by rumored private distributors and open associations. Statistical surveying Store is the far-reaching gathering of market knowledge items and administrations accessible on air. We have statistical surveying reports from a number of driving distributors and update our gathering day by day to furnish our customers with the moment online access to our database. With access to this database, our customers will have the option to profit by master bits of knowledge on worldwide businesses, items, and market patterns

Contact Us:

Lexis Business Insights

Aaryan

(Director- Business Development)

US: +1 210 907 4145

UK: +44 7880 533158

[emailprotected]

http://www.lexisbusinessinsights.com

We are a vibrant market research company which is focused on catering to more and more people day by day. Our research company is one of a few reliable market research report companies in todays date.

See the original post here:
Global Regenerative Medicine Market expected to Growth at an impressive CAGR during the period of 2020-2025 - Fusion Science Academy

Read More...

Sports Medicine Market to Expand at a Healthy Growth Rate in the Coming Years – Press Release – Digital Journal

Tuesday, January 21st, 2020

North America is expected to hold a significant share in the sports medicine market during the forecast period

This press release was orginally distributed by SBWire

Northrook, IL -- (SBWIRE) -- 01/20/2020 -- Growth in the sports medicine analysis market can be attributed to factors such as the increasing incidence of sports injuries, continuous influx of new products & treatment modalities, and developments in the field of regenerative medicine. On the other hand, the high cost of implants and other devices and the dearth of skilled professionals are expected to limit market growth to a certain extent during the forecast period.

What the Market Looks Like?

Predicted to grow at a CAGR of 6.5% during the forecast period, the global sports medicine market is estimated to reach USD 9.1 Billion by the end of 2024. Factors such as the rising popularity of sports and physical activity, increasing awareness regarding the prevention & treatment of sports injuries, and growing investments in sports medicine are driving the North American market.

On the basis of products, the sports medicine market is segmented into body reconstruction products (fracture & ligament repair products, arthroscopy devices, implants, prosthetics, orthobiologics), body support & recovery products (braces & support, physiotherapy equipment, and compression clothing), and accessories. The body support & recovery products segment is expected to witness the fastest growth during the forecast period. Products such as braces, supports, and physiotherapy equipment are required before and after procedures involving reconstruction. Thus, the demand for these devices is growing due to the increasing number of sports injuries globally.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=751

Sports medicine is widely used for the prevention of sports injuries as well as for the cure, recovery, and rehabilitation of athletes. The sports medicine applications market is segmented into knee injuries, shoulder injuries, foot & ankle, elbow & wrist, back & spine, hip & groin, and other injuries. The knee injuries segment held the largest share of the market in 2018, a trend that is expected to continue during the forecast period. The large share of this segment can be attributed to the fact that a large number of knee injuries are recorded across major sports, globally, accounting for approximately 40% of all injuries due to sports.

What Drives the Market?

The growth of the global market for sports medicine is primarily influenced by the following factors:

- Increasing Incidence of Sports Injuries - Continuous Influx of New Products and Treatment Modalities - Developments in the Field of Regenerative Medicine

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=751

Geographical growth scenario of Sports Medicine Market:

Geographically, North America is expected to dominate the global sports medicine market in 2018, while the Asia Pacific region is expected to register the highest CAGR during the forecast period.

The high growth in this region can be attributed to the growth of the sports industry and overall participation in sports. Sporting events such as the 2008 Beijing Olympics, 2018 Winter Olympics in Korea, and the upcoming 2020 Summer Olympics in Japan have increased the level of interest in sports in Asia.

Leading market players and strategies adopted:

The major players operating in the sports medicine market include Arthrex, Inc (US), Smith & Nephew plc (UK), and Stryker Corporation (US). Other players involved in this market include Breg Inc. (US), DJO Global, Inc. (US), Mueller Sports, Inc. (US), Wright Medical Group N.V. (US), Medtronic (Ireland), RTI Surgical (US), Performance Health International Limited (US), KARL STORZ (Germany), and Bauerfeind AG (US).

Request Bundle Reports: https://www.marketsandmarkets.com/RequestBundleReport.asp?id=751

About MarketsandMarketsMarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Shelly SinghMarketsandMarkets INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA : 1-888-600-6441sales@marketsandmarkets.com

For more information on this press release visit: http://www.sbwire.com/press-releases/sports-medicine-market-to-expand-at-a-healthy-growth-rate-in-the-coming-years-1271600.htm

Original post:
Sports Medicine Market to Expand at a Healthy Growth Rate in the Coming Years - Press Release - Digital Journal

Read More...

Stem Cell Assay Market to Expand at a Healthy CAGR of XX% Between and 2017 2025 Dagoretti News – Dagoretti News

Tuesday, January 21st, 2020

In 2019, the market size of Stem Cell Assay Market is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2019 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Stem Cell Assay .

This report studies the global market size of Stem Cell Assay , especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=40&source=atm

This study presents the Stem Cell Assay Market production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Stem Cell Assay history breakdown data from 2014 to 2019, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global Stem Cell Assay market, the following companies are covered:

growth drivers and lists down the major restraints. Additionally, the report gauges the effect of Porters five forces on the overall stem cell assay market.

Global Stem Cell Assay Market: Key Market Segments

For the purpose of the study, the report segments the global stem cell assay market based on various parameters. For instance, in terms of assay type, the market can be segmented into isolation and purification, viability, cell identification, differentiation, proliferation, apoptosis, and function. By kit, the market can be bifurcated into human embryonic stem cell kits and adult stem cell kits. Based on instruments, flow cytometer, cell imaging systems, automated cell counter, and micro electrode arrays could be the key market segments.

In terms of application, the market can be segmented into drug discovery and development, clinical research, and regenerative medicine and therapy. The growth witnessed across the aforementioned application segments will be influenced by the increasing incidence of chronic ailments which will translate into the rising demand for regenerative medicines. Finally, based on end users, research institutes and industry research constitute the key market segments.

The report includes a detailed assessment of the various factors influencing the markets expansion across its key segments. The ones holding the most lucrative prospects are analyzed, and the factors restraining its trajectory across key segments are also discussed at length.

Global Stem Cell Assay Market: Regional Analysis

Regionally, the market is expected to witness heightened demand in the developed countries across Europe and North America. The increasing incidence of chronic ailments and the subsequently expanding patient population are the chief drivers of the stem cell assay market in North America. Besides this, the market is also expected to witness lucrative opportunities in Asia Pacific and Rest of the World.

Global Stem Cell Assay Market: Vendor Landscape

A major inclusion in the report is the detailed assessment of the markets vendor landscape. For the purpose of the study the report therefore profiles some of the leading players having influence on the overall market dynamics. It also conducts SWOT analysis to study the strengths and weaknesses of the companies profiled and identify threats and opportunities that these enterprises are forecast to witness over the course of the reports forecast period.

Some of the most prominent enterprises operating in the global stem cell assay market are Bio-Rad Laboratories, Inc (U.S.), Thermo Fisher Scientific Inc. (U.S.), GE Healthcare (U.K.), Hemogenix Inc. (U.S.), Promega Corporation (U.S.), Bio-Techne Corporation (U.S.), Merck KGaA (Germany), STEMCELL Technologies Inc. (CA), Cell Biolabs, Inc. (U.S.), and Cellular Dynamics International, Inc. (U.S.).

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=40&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Stem Cell Assay product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Stem Cell Assay , with price, sales, revenue and global market share of Stem Cell Assay in 2017 and 2019.

Chapter 3, the Stem Cell Assay competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Stem Cell Assay breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=40&source=atm

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.

Chapter 12, Stem Cell Assay market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.

Chapter 13, 14 and 15, to describe Stem Cell Assay sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Go here to see the original:
Stem Cell Assay Market to Expand at a Healthy CAGR of XX% Between and 2017 2025 Dagoretti News - Dagoretti News

Read More...

Amnion of Florida Announces Greater Geographic Reach for Their Regenerative Health Services by Partnering With Care First Medical Group – Business…

Friday, January 3rd, 2020

ORLANDO, Fla.--(BUSINESS WIRE)--Amnion of Florida, a leading provider of alternative medicine utilizing cryopreserved placental cell allograft for advanced bioactive facial rejuvenation, is pleased to announce a partnership to enhance patient outcomes for joint pain and anti-aging therapies.

Amnion announces a partnership with Care First Medical Group, Inc. to improve patients experience with managed medical care and provide non-pharmaceutical solutions for joint repair/pain management and anti-aging. The goals of the collaboration are to provide alternatives to medical care and to help patients seeking to eliminate chronic joint pain, look younger, and take a more active role in mapping their medical care to avoid illness in the future.

Sabriya Rogers, President of Care First, states, Our Board-Certified primary care providers specialize in managed health, thus patients can take a proactive approach in deciding the course of their care, which yields a lower cost to patients, while keeping families together, and maintaining a high degree of medical care.

The partnership will provide more location options for patients. With offices throughout greater Orlando, Sanford, Leesburg, Palm Coast, and Longwood, patients will find a location nearby that fits busy schedules.

Our team of medical professionals and aestheticians at Amnion are excited to partner with Care First to provide enhanced medical care and rejuvenation services at our partnership locations, said Eusebio Coterillo, President of Amnion.

In a constantly changing field, Amnion of Florida, under the guidance of an on-site medical staff, provides the highest level of quality products and procedures in regenerative medicine. They offer cutting edge treatments that are shown to be effective, use FDA cleared or registered products, and are widely published and peer endorsed. The collaboration with Care First will bring added benefits such as managed care, urgent care, and programmed care for long term issues such as high blood pressure, diabetes, high cholesterol, asthma, and allergies in a full-service clinical setting.

More about Amnion of Florida

Amnion of Florida, based in Central Florida, is a leading provider of alternative medicine using cryopreserved placental cell transplants or allografts, processed from donated cellular birth tissue, which are natural alternatives to autologous regenerative medicine products. The primary function of our allogeneic regenerative treatments is to promote soft tissue joint/skin repair and regeneration mediated by growth factors and cells naturally found in placental tissue. These treatments have shown safety and efficacy in treating a variety of ailments including osteoarthritis, chronic ulcerative wounds, joint pain, skin rejuvenation, hair restoration, urinary incontinence, and ED. Learn more at http://www.amnion.us.

More about Care First Medical Group, Inc.

Care First, based in Central Florida, is focused on providing affordable healthcare for primary and urgent care needs through prevention, patient education, with the personal touch to improve communication with the patient, and patients overall health. Our vision is to transform the health care experience through a culture of caring, quality, safety, service, innovation, and excellence. Our goal is to be recognized by employees, physicians, patients and families, volunteers, and the community as a company that delivers results through our proactive approach to medicine. Learn more or schedule an appointment at (407) 449-0632.

Read this article:
Amnion of Florida Announces Greater Geographic Reach for Their Regenerative Health Services by Partnering With Care First Medical Group - Business...

Read More...

BrainStorm Cell Therapeutics Wins 2020 ‘Buzz of BIO’ Award for ALS Investigational Therapy – ALS News Today

Friday, January 3rd, 2020

For its promising investigational therapeutic approach to neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), BrainStorm Cell Therapeutics is theBuzz of BIO 2020 winnerin the Public Therapeutic Biotech category.

The Buzz of BIO contest identifies U.S. companies with groundbreaking, early-stage potential to improve lives. The event also is anopportunity to make investor connections that could take products to the next phase.

Ten biotechnology companies are nominated in each of the three categories ofBuzz of BIO: Public Therapeutic Biotech, Private Therapeutic Biotech, and Diagnostics and Beyond. In the Public Therapeutic Biotech category that BrainStorm won, nominated companies must be actively developing a publicly traded human treatment intended for review by theU.S. Food and Drug Administration (FDA).

As a developer of autologous cellular therapies treatments that use a patients own cells and tissues for debilitating neurodegenerative diseases, BrainStorm is now testing its NurOwn therapy for safety and effectiveness. The treatment involves extracting, from human bone, marrow-derived mesenchymal stem cells (MSCs), which are capable of differentiating into other cell types. The MSCs are then matured into a specific cell type that produces neurotrophic factors compounds that promote nervous tissue growth and survival. They are then reintroduced to the body via injection into muscles and/or the spinal canal.

Backed by a California Institute for Regenerative Medicine grant, Brainstorm has fully enrolledits randomized, double-blind, placebo-controlled Phase 3 clinical trial (NCT03280056) at six U.S. sites in California, Massachusetts, and Minnesota. Some 200 ALS patients are participating. A secondary safety analysis by the trials independent Data Safety Monitoring Board (DSMB) revealed no new concerns. Every two months, study subjects will be given three injections into the spinal canal of either NurOwn or placebo.

The trial is expected to conclude late this year. Results will be announced shortly afterward.

In a Phase 2 study (NCT02017912), which included individuals with rapidly progressing ALS, NurOwn demonstrated a positive safety profile as well as prospective efficacy.

The use of autologous MSC cells to potentially treat ALS was given orphan drug status by both the FDA and the European Medicines Agency.

Thanks to everyone who voted for BrainStorm during the Buzz of BIO competition,Chaim Lebovits, BrainStorm president and CEO, said in a press release. The entire management team at BrainStorm was very pleased with the results of this competition, and we look forward to presenting to an audience of accredited investors who may benefit from the companys story. We thank the BIO[Biotechnology Innovation Organization] team for singling out BrainStorms NurOwn as a key technology with the potential to improve lives.

As a contest winner, BrainStorm is invited to givea presentation at theBio CEO & Investor Conference, to be held Feb. 1011 in New York City, along with exposure to multiple industry elites and potential investors.

NurOwn cells also are being tested in a Phase 2 clinical study (NCT03799718) in patients with progressive multiple sclerosis.

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours dElegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled Belle of the Concours.

Total Posts: 6

Ins holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Cincias e Tecnologias and Instituto Gulbenkian de Cincia. Ins currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.

Link:
BrainStorm Cell Therapeutics Wins 2020 'Buzz of BIO' Award for ALS Investigational Therapy - ALS News Today

Read More...

Rexgenero CEO Talks Importance of Dialogue in Cell Therapy Conversations – Xconomy

Friday, January 3rd, 2020

XconomyNational

Cell and gene therapies are becoming more mainstream, but an essential aspect of the drug development process is talking with clinicians about how it would fit into their practice, according to Joe Dupere, CEO of UK-based regenerative medicine company Rexgenero.

Rexgenero is advancing an experimental cell therapy for critical limb ischemia, a chronic condition that causes severe burning pain in the feet or toes as a result of blocked arteries in the lower limbs. Patients often get ulcers that can lead to amputation of the affected limb.

The company, headquartered in London, has R&D and manufacturing operations in Spain. Dupere talked with journalist Mike Ward at BIO-Europe 2019 in Hamburg, Germany, about the companys progress and plans.

Theres a lot of dialogue with the physicians and the surgeons that we cooperate with in our trial so they understand our product, its place in the treatment of this disease, and understanding when they can bring in patients and potential benefits, Dupere said.

When it comes to involving clinicians in its studies, the earlier, the better, Dupere said he learned as the company advanced its investigational treatments.

We live and breathe our design of our study, but surgeons are coming into this new, and to really understand how it works and really assist them in that journey with us so that they can bring patients in, we make it as easy as possible for them to participate, he said.

Although the type of treatment isnt as unusual as it once was, detailing how Rexgeneros cell therapies could impact how care is currently provided is essential to getting buy-in from the physicians who would use it, he said.

The challenge for us is to really demonstrate the superiority, in terms of the efficacy that we can show, and how that fits in with their practice, he said. Thats also marrying what they do already, which is a series of surgical and in endovascular procedures, [with] where the cell therapies can come in and really turbocharge that and have a really substantial impact on their patients.

As Rexgenero focuses on its Phase 3 trials, its priorities have included thinking through how the product would be used if it were to make it to commercialization.

Theres a whole range of other activities that we need to focus on as we get nearer to the market, he said.One is scaling up the manufacture, so thats a truly commercial manufacturing process that can really deliver the product to as many patients as possible. The second is really understanding how this would be used in practice, so from a commercial perspective, how would you sell this product, how would you position it with the physicians, and how would you get the surgeons to understand where this treatment would work in their general practice.

Duprere said the company also aims to expand into supplementary indications and establish a presence in the US.

Talking with investors as BIO-Europe, Duprere said he noticed more of an appreciation for biotechs that are doing cell therapy work outside of immune-oncology, a hot area for life sciences financings.

I think when you talk about [strategic investors], the core value proposition of the disease and the treatment of the disease and the unmet need of the disease has been understood from the beginning, but utilization of a cell therapy to be able to address that market is something that theyre getting much more familiar with, certainly around things like the manufacture, some of the regulation thats specific to cell therapies, and also the commercial path, when youre dealing with a curative product where you give a single dose of the product and you expect a cure for the patient.

Sarah de Crescenzo is an Xconomy editor based in San Diego. You can reach her at sdecrescenzo@xconomy.com.

View original post here:
Rexgenero CEO Talks Importance of Dialogue in Cell Therapy Conversations - Xconomy

Read More...

Glaucoma Research Foundation to Host 9th Annual Glaucoma 360 at Grand Hyatt in San Francisco – Newswise

Friday, January 3rd, 2020

MEDIA CONTACT

Available for logged-in reporters only

9th Annual Glaucoma 360, February 6 to 8, 2020, San Francisco

Newswise San Francisco, CA January 2, 2020: Glaucoma Research Foundation (GRF) will host the 9th Annual Glaucoma 360 from February 6 to 8, 2020 in San Francisco. This signature three-day event highlights innovation in glaucoma therapies to ensure patients have access to the latest and most effective diagnostic tools and treatment options. All Glaucoma 360 events will take place at the Grand Hyatt San Francisco in Union Square.

Glaucoma 360 begins on Thursday evening (February 6th) with a fundraising Gala. At the Gala, the 2020 Catalyst Award will be presented toVicente Anido, Jr, PhD and Thomas A. Mitro from Aerie Pharmaceuticals, Inc., in recognition of their remarkable leadership and commitment to the development of innovative glaucoma treatments.

During the Gala, Glaucoma Research Foundation will also be recognizing extraordinary research with the following presentations:

The New Horizons Forum on February 7th will feature more than 60 speakers from companies developing innovative glaucoma therapies and diagnostics. This full-day meeting co-founded and co-chaired byAdrienne L. Graves, PhDandAndrew G. Iwach, MD, spotlights new and promising developments to diagnose and treat glaucoma, a leading cause of preventable blindness worldwide. Since its inception in 2012, this meeting has grown substantially, attracting key clinical, scientific, industry, financial, and regulatory leaders from across the United States and around the world.

We will once again feature early-stage companies and their new technologies and approaches to glaucoma care, said Dr. Graves. The amount of innovation that is flourishing in the glaucoma space right now is phenomenal. As a result, there are more therapeutic options than ever before to help patients. Glaucoma 360 is an important catalyst to bring all the important elements together that can advance a promising idea into clinical use, she said.

Dr. Iwach added, For our 2020 New Horizons Forum, in addition to highlighting new developments in glaucoma diagnostics and therapies, there will also be a session on Innovation 101 that will discuss how you move from a great idea into the next breakthrough therapy for patients. The FDA will be involved in this session as their guidance is critical to get new and more effective solutions to our patients.

David W. Parke II, MD, Chief Executive Officer of the American Academy of Ophthalmology (AAO), will deliver the Drs. Henry and Frederick Sutro Memorial Lecture, the Forums keynote address. Dr. Parkes lecture, When Cost and Innovation Collide in Ophthalmology, will highlight the Academys role in facilitating innovation through collaboration with industry partners, AAO members, and AAO resources such as the IRIS registry the nation's first comprehensive eye disease clinical registry.

Glaucoma 360 will conclude on Saturday, February 8th with continuing medical education symposia for ophthalmologists and optometrists. The Shaffer-Hetherington-Hoskins Keynote Lecture on Saturday morning will be presented byDale K. Heuer, MD, Retired Professor and Chair of Ophthalmology and Visual Sciences, Medical College of Wisconsin in Milwaukee. More than 1,000 attendees are expected to participate over the three days of Glaucoma 360. All proceeds from the events support Glaucoma Research Foundations research and educational programs. To learn more about Glaucoma 360 events and to register, visit:www.glaucoma360.org.

About Glaucoma Research Foundation

Founded in San Francisco in 1978, Glaucoma Research Foundation is Americas oldest and most experienced institution dedicated to its mission to cure glaucoma and restore vision through innovative research. The Foundation has a proven track record of pioneering, results-oriented research and produces definitive educational materials used by eye care professionals across the country. The Glaucoma Research Foundation website,www.glaucoma.org, provides valuable information about glaucoma to 4 million visitors annually.

For more information about Glaucoma Research Foundation and Glaucoma 360 events, please contact, Brizette Castellanos at 415.986.3162, ext. 221, or brizette@glaucoma.org or visitwww.glaucoma360.org.

Continue reading here:
Glaucoma Research Foundation to Host 9th Annual Glaucoma 360 at Grand Hyatt in San Francisco - Newswise

Read More...

Supply Chain Management Software Solutions Market Will Grow Significantly in Coming Years – Supply and Demand Chain Executive

Friday, January 3rd, 2020

Cell and Advanced Therapies Supply Chain Management Market: Focus on Technological Solutions, 2019-2030report features an extensive study of the growing supply chain management software solutions market.

The focus of this study is on software systems, including cell orchestration platforms (COP), enterprise manufacturing systems (EMS), inventory management systems (IMS), laboratory information management systems (LIMS), logistics management systems (LMS), patient management systems (PMS), quality management systems (QMS), tracking and tracing software (TTS), and other such platforms that are being used to improve / optimize various supply chain-related processes of cell and advanced therapies.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the supply chain management software solutions market. Based on multiple parameters, such as number of cell and advanced therapies under development, expected pricing, likely adoption rates, and potential cost saving opportunities from different software systems, we have developed informed estimates of the evolution of the market, over the period 2019-2030.

In addition, we have provided the likely distribution of the current and forecasted opportunity across:

Advanced therapy medicinal products, such as cell and gene therapies, have revolutionized healthcare practices. The introduction of such treatment options has led to a paradigm shift in drug development, production and consumption. Moreover, such therapies have actually enabled healthcare providers to treat several difficult-to-treat clinical conditions.

In the past two decades, more than 30 such therapy products have been approved; recent approvals include Zolgensma (2019), RECELL System (2018), AmnioFix (2018), EpiFix (2018), EpiBurn (2018), Alofisel (2018), LUXTURNA (2017), Yescarta (2017), and Kymriah (2017). Further, according to a report published by The Alliance for Regenerative Medicine in 2019, more than 1,000 clinical trials are being conducted across the globe by over 900 companies.

In 2018, around USD 13 billion was invested in this domain, representing a 73% increase in capital investments in this domain, compared to the previous year. It is worth highlighting that, based on an assessment of the current pipeline of cell therapies and the historical clinical success of such products, it is likely that around 10-20 advanced therapies are approved by the US FDA each year, till 2025.

The commercial success of cell and advanced therapies is not only tied to whether they are capable of offering the desired therapeutic benefits, but also on whether the developers are able to effectively address all supply chain requirements. The advanced therapy medicinal products supply chain is relatively more complex compared to the conventional pharmaceutical supply chain. As a result, there are a number of risks, such as possible operational inefficiencies, capacity scheduling concerns, process delays leading to capital losses, and deliverable tracking-related issues, which need to be taken into consideration by therapy developers.

This has generated a need for bespoke technological solutions, which can be integrated into existing processes to enable the engaged stakeholders to oversee and manage the various aspects of the cell and advanced therapies supply chain, in compliance to global regulatory standards. Over the years, several innovative, software-enabled systems, offering supply chain orchestration and needle-to-needle traceability, have been developed.

The market has also recently witnessed the establishment of numerous partnerships, most of which are agreements between therapy developers and software solutions providers. Further, given the growing demand for cost-effective personalized medicinal products, and a myriad of other benefits of implementing such software solutions, the niche market is poised to grow significantly in the foreseen future.

Amongst other elements, the report features:

In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry's evolution.

Continue reading here:
Supply Chain Management Software Solutions Market Will Grow Significantly in Coming Years - Supply and Demand Chain Executive

Read More...

Inside Indiana’s Precision Health Initiative: BTN LiveBIG – Big Ten Network

Friday, January 3rd, 2020

At the 200-year mark, some institutions would be content to rest on their laurels. But not Indiana University. As their bicentennial celebrations nears, the Hoosiers have dedicated themselves to a tackling what they are calling Grand Challenges, a suite of economic, social and environmental problems plaguing Indiana and the world. These challenges are marked by their impressive scale, immense impact, driven commitment to solutions, and a spirit of interdisciplinary collaboration.

One of the Grand Challenges is the Precision Health Initiative, which aims to match patients more closely and carefully with treatments that meet their individual needs. According to Anatha Shekhar, the executive associate dean of research affairs at the Indiana University School of Medicine, the initiative derives that precision by taking a decidedly holistic look at a patient's health.

"What we're trying to do here is to have a comprehensive approach to understanding a person's health, taking into account their genetics, their environment, their behavior, their culture, and to understand the diseases that are caused by these factors," Shekar explains. "We're particularly focusing on five major serious illnesses that currently have no good treatments and that are uniformly lethal or disabling."

Those five diseases include three types of cancer: triple-negative breast cancer, multiple myeloma, and pediatric sarcoma. They're also targeting diabetes, in particular gestational diabetes affecting pregnant women, as well as Alzheimer's disease.

The Precision Health Initiative was the first project to receive Grand Challenges funding. A truly transformative undertaking, Indiana is pulling together researchers and physicians from across the university ecosystem to create new approaches to prevention, treatment and health care delivery.

"The Precision Health Initiative is trying to just marshal the great resources we have here, all the scientific minds, all the technology, to attack big, bold problems," says Aaron Carroll, professor of pediatrics and associate dean for research mentoring at the IU School of Medicine.

The project is funneling $120 million into six different major scientific pillars: Genomic Medicine; Cell, Gene & Immune Therapy; Regenerative Medicine & Engineering; Psychosocial, Behavioral & Ethics; Data & Informatics; and Chemical Biology & Biotherapeutics.

Carroll likens it all to a moonshot. Where research is normally understood to move slowly, taking tiny steps towards a solution, Indiana seeks great strides founded in unfettered access to both real and mental capital. And, as the only medical school in the state, as well as a regional and national research leader, their charge is an imperative. "It's certainly very Hoosier. I think the idea that we're going to take our local expertise and really try to band together and cross boundaries to try to make a big difference, it's, it's very Indiana," Carroll says.

Clinically speaking, the Precision Health Initiative is not just seeking to draw down instances of the maladies their targeting. Rather, they seek wholesale cures for the cancers, and robust, workable preventative measures for diabetes and Alzheimer's disease.

Their patient-focused approach is already being taught to physicians-in-training at the IU School of Medicine. The importance of factors such as genetic and family medical history, sleep and eating habits, exercise levels and overall mental health is emphasized alongside traditional testing in making a diagnosis.

In the lab, Indiana researchers are matching that holistic approach to patient health with an equally vibrant understanding of how diseases operate. They're working towards a more-perfect model of exactly how cancers evolve and how they become resistant to certain treatments. Concurrently, pharmaceutical scientists are making gains in drug discovery for the treatment of Alzheimer's.

Shekhar says that the feeling among the Precision Health Initiative team is that the work being done now is serving as inspiration for others to "think big and to go for the fences rather than do incremental work."

There are, though, factors limiting the speed at which the team can make new discoveries. Key among them is the need for an expansion in data analysis and management as well as advances need in AI to help researchers make sense of extremely large data sets.

One such set derives from the All In project, which is under the Precision Health Initiative umbrella. Researchers are asking people from across the state and all walks of life to share with them a blood sample as well as specific, yet anonymous health data. This will aid immensely in their understanding of how and why diseases flourish and progress in various populations.

That particular project is indicative of the larger initiative, says Shekhar, echoing Carroll's sentiment that Indiana is uniquely positioned to helm such an audacious undertaking.

"I think Indiana is unique in that first of all, we have the largest medical school in the country, that is a state wide medical school with nine campuses," he says. "We have the largest health system in the state. We serve about two million people every year for their health needs. So, we have gone all the way from engaging large scientific teams, recruiting nearly 50 new scientists to Indiana University to work on this, to engaging nearly hundred thousand people from the community. It's an initiative that couldn't happen in very many places except in Indiana."

See the rest here:
Inside Indiana's Precision Health Initiative: BTN LiveBIG - Big Ten Network

Read More...

Cell and Advanced Therapies Supply Chain Management Industry Report, 2019-2030 – GlobeNewswire

Friday, January 3rd, 2020

Dublin, Jan. 03, 2020 (GLOBE NEWSWIRE) -- The "Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological Solutions" report has been added to ResearchAndMarkets.com's offering.

Cell and Advanced Therapies Supply Chain Management Market: Focus on Technological Solutions, 2019-2030 report features an extensive study of the growing supply chain management software solutions market.

The focus of this study is on software systems, including cell orchestration platforms (COP), enterprise manufacturing systems (EMS), inventory management systems (IMS), laboratory information management systems (LIMS), logistics management systems (LMS), patient management systems (PMS), quality management systems (QMS), tracking and tracing software (TTS), and other such platforms that are being used to improve / optimize various supply chain-related processes of cell and advanced therapies.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the supply chain management software solutions market. Based on multiple parameters, such as number of cell and advanced therapies under development, expected pricing, likely adoption rates, and potential cost saving opportunities from different software systems, we have developed informed estimates of the evolution of the market, over the period 2019-2030.

In addition, we have provided the likely distribution of the current and forecasted opportunity across:

Advanced therapy medicinal products, such as cell and gene therapies, have revolutionized healthcare practices. The introduction of such treatment options has led to a paradigm shift in drug development, production and consumption. Moreover, such therapies have actually enabled healthcare providers to treat several difficult-to-treat clinical conditions.

In the past two decades, more than 30 such therapy products have been approved; recent approvals include Zolgensma (2019), RECELL System (2018), AmnioFix (2018), EpiFix (2018), EpiBurn (2018), Alofisel (2018), LUXTURNA (2017), Yescarta (2017), and Kymriah (2017). Further, according to a report published by The Alliance for Regenerative Medicine in 2019, more than 1,000 clinical trials are being conducted across the globe by over 900 companies.

In 2018, around USD 13 billion was invested in this domain, representing a 73% increase in capital investments in this domain, compared to the previous year. It is worth highlighting that, based on an assessment of the current pipeline of cell therapies and the historical clinical success of such products, it is likely that around 10-20 advanced therapies are approved by the US FDA each year, till 2025.

The commercial success of cell and advanced therapies is not only tied to whether they are capable of offering the desired therapeutic benefits, but also on whether the developers are able to effectively address all supply chain requirements. The advanced therapy medicinal products supply chain is relatively more complex compared to the conventional pharmaceutical supply chain. As a result, there are a number of risks, such as possible operational inefficiencies, capacity scheduling concerns, process delays leading to capital losses, and deliverable tracking-related issues, which need to be taken into consideration by therapy developers.

This has generated a need for bespoke technological solutions, which can be integrated into existing processes to enable the engaged stakeholders to oversee and manage the various aspects of the cell and advanced therapies supply chain, in compliance to global regulatory standards. Over the years, several innovative, software-enabled systems, offering supply chain orchestration and needle-to-needle traceability, have been developed.

The market has also recently witnessed the establishment of numerous partnerships, most of which are agreements between therapy developers and software solutions providers. Further, given the growing demand for cost-effective personalized medicinal products, and a myriad of other benefits of implementing such software solutions, the niche market is poised to grow significantly in the foreseen future.

Amongst other elements, the report features:

In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry's evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

Key Topics Covered

1. PREFACE1.1. Scope of the Report1.2. Research Methodology1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION3.1. Context and Background3.2. An Introduction to Cell and Advanced Therapies3.2.1. Classification of Advanced Therapy Medicinal Products3.2.2. Current Market Landscape3.3. Cell and Advanced Therapies Supply Chain3.3.1. Key Processes3.3.2. Challenges Associated with the Cell and Advanced Therapies Supply Chain3.4. Software Solutions for Cell and Advanced Therapies Supply Chain Management3.4.1. Cell Orchestration Platform3.4.2. Enterprise Manufacturing System3.4.3. Inventory Management System3.4.4. Laboratory Information Management System3.4.5. Logistics Management System3.4.6. Patient Management System3.4.7. Quality Management System3.4.8. Tracking and Tracing System3.5. Growth Drivers and Roadblocks3.6. Emergence of Digital Technologies in Supply Chain Management3.6.1. Blockchain Technology3.6.2. Internet of Things3.6.3. Augmented Reality3.6.4. Big Data Analytics3.6.5. Artificial Intelligence

4. CURRENT MARKET LANDSCAPE4.1. Chapter Overview4.2. Cell and Advanced Therapies Supply Chain Management: Overall Market Landscape4.2.1. Analysis by Type of Software Solution4.2.2. Analysis by Key Specification and Benefit4.3.3. Analysis by Application4.3.4. Analysis by End User4.3.5. Analysis by Mode of Deployment4.3.6. Analysis by Scale of Management4.3.7. Analysis by Regulatory Certifications / Accreditations4.3. Cell and Advanced Therapies Supply Chain Management: Developer Landscape4.2.1. Analysis by Year of Establishment4.2.2. Analysis by Location of Headquarters4.2.3. Analysis by Size of Company4.3.4. Analysis by Support Services Offered4.3.5. Leading Developers: Analysis by Number of Software Solutions

5. COMPANY COMPETITIVENESS ANALYSIS5.1. Chapter Overview5.2. Methodology5.3. Assumptions and Key Parameters5.4. Competitiveness Analysis: Overview of Supply Chain Management Software Solution Providers5.4.1. Small-sized Companies5.4.2. Mid-sized Companies5.4.3. Large Companies

6. CORE SUPPLY CHAIN MANAGEMENT SOFTWARE SOLUTIONS: COMPANY PROFILES6.1. Chapter Overview6.2. Brooks Life Sciences6.2.1. Company Overview6.2.2. Financial Information6.2.3. BiobankPro: Software Description6.2.4. Recent Developments and Future Outlook6.3. Cryoport6.3.1. Company Overview6.3.2. Financial Information6.3.3. Cryoportal: Software Description6.3.4. Recent Developments and Future Outlook6.4. MasterControl6.4.1. Company Overview6.4.2. MasterControl Platform: Software Description6.4.3. Recent Developments and Future Outlook6.5. SAP6.5.1. Company Overview6.5.2. Financial Information6.5.3. SAP S/4HANA: Software Description6.5.4. Recent Development and Future Outlook6.6. Savsu Technologies6.6.1. Company Overview6.6.2. Financial Information6.6.3. evo Cold Chain 2.0: Software Description6.6.4. Recent Development and Future Outlook6.7. TraceLink6.7.1. Company Overview6.7.2. Financial Information6.7.3. Digital Supply Chain Platform: Software Description6.7.4. Recent Developments and Future Outlook

7. CELL ORCHESTRATION PLATFORMS: EMERGING TRENDS AND PROFILES OF KEY PLAYERS7.1. Chapter Overview7.2. Supply Chain Orchestration Platforms7.2.1. Key Functions of Supply Chain Orchestration Platforms7.2.2. Advantages of Supply Chain Orchestration Platforms7.2.3. Supply Chain Orchestration Platform Implementation Strategies7.3. Supply Chain Orchestration Platform: Trends on Twitter7.3.1. Scope and Methodology7.3.2. Historical Trends in Volume of Tweets7.3.3. Popular Keywords7.4. Key Industry Players7.4.1. Be The Match BioTherapies7.4.2. Clarkston Consulting7.4.3. Haemonetics7.4.4. Hypertrust Patient Data Care7.4.5. Lykan Bioscience7.4.6. MAK-SYSTEM7.4.7. sedApta Group7.4.8. Stafa Cellular Therapy7.4.9. Title 21 Health Solutions7.4.10. TrakCel7.4.11. Vineti

8. FUNDING AND INVESTMENT ANALYSIS8.1. Chapter Overview8.2. Types of Funding8.3. Cell and Advanced Therapies Supply Chain Management: Recent Funding Instances8.3.1. Analysis by Number of Funding Instances8.3.2. Analysis by Amount Invested8.3.3. Analysis by Type of Funding8.3.4. Analysis by Number of Funding Instances and Amount Invested across Different Software Solutions8.3.5. Most Active Players: Analysis by Amount Invested8.3.6. Most Active Investors: Analysis by Participation8.3.7. Geographical Analysis by Amount Invested8.4. Concluding Remarks

9. PARTNERSHIPS AND COLLABORATIONS9.1. Chapter Overview9.2. Partnership Models9.3. Cell and Advanced Therapies Supply Chain Management: Recent Collaborations and Partnerships9.3.1. Analysis by Year of Partnership9.3.2. Analysis by Type of Partnership9.3.3. Analysis by Partner's Focus Area9.3.4. Analysis by Type of Software Solution9.3.5. Most Active Players: Analysis by Number of Partnerships9.3.6. Analysis by Regions

10. PLATFORM UTILIZATION USE CASES10.1. Chapter Overview10.2. Cell and Advanced Therapies Supply Chain Management: Recent Platform Utilization Use Cases10.2.1. Analysis by Year of Utilization10.2.2. Analysis by User's Focus Area10.2.3. Analysis by Type of Software Solution10.2.4. Most Active Players: Analysis by Number of Utilization Instances10.2.5. Most Active Players: Regional Analysis by Number of Utilization Instances

11. VALUE CHAIN ANALYSIS11.1. Chapter Overview11.2. Cell and Advanced Therapies Value Chain11.2. Cell and Advanced Therapies Value Chain: Cost Distribution11.3.1. Donor Eligibility Assessment11.3.2. Sample Collection11.3.3. Manufacturing11.3.4. Logistics11.3.5. Patient Verification and Treatment Follow-up

12. STAKEHOLDER NEEDS ANALYSIS12.1. Chapter Overview12.2. Cell and Advanced Therapies Supply Chain Management: Needs of Different Stakeholders12.2.1. Comparison of Stakeholder Needs

13. COST SAVINGS ANALYSIS13.1. Chapter Overview13.2. Key Assumptions and Methodology13.3. Overall Cost Saving Potential of Supply Chain Management Software Solutions, 2019-203013.3.1. Cost Saving Potential in Donor Eligibility Assessment, 2019-203013.3.2. Cost Saving Potential in Sample Collection, 2019-203013.3.3. Cost Saving Potential in Manufacturing, 2019-203013.3.4. Cost Saving Potential in Logistics, 2019-203013.3.5. Cost Saving Potential in Patient Verification and Treatment Follow-up, 2019-2030

14. MARKET FORECAST14.1. Chapter Overview14.2. Key Assumptions and Forecast Methodology14.3. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, 2019-203014.3.1. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application14.3.2. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User14.3.3. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution14.3.4. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment14.3.5. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography14.4. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Type of Software Solution and Mode of Deployment14.4.1. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, 2019-203014.4.2. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, 2019-203014.4.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, 2019-203014.4.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, 2019-203014.4.5. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030

15. EXECUTIVE INSIGHTS15.1. Chapter Overview15.2. Thermo Fisher Scientific15.2.1. Company Snapshot15.2.2. Interview Transcript: Bryan Poltilove, Vice President and General Manager15.3. Cell and Gene Therapy Catapult15.3.1. Company Snapshot15.3.2. Interview Transcript: Jacqueline Barry, Chief Clinical Officer15.4. McKesson15.4.1. Company Snapshot15.4.2. Interview Transcript: Jill Maddux, Director, Cell and Gene Therapy Product Strategy, and Divya Iyer, Senior Director, Corporate Strategy and Business Development15.5. TrakCel15.5.1. Company Snapshot15.5.2. Interview Transcript: Martin Lamb, Chief Business Officer

16. CONCLUDING REMARKS16.1. Chapter Overview16.2. Key Takeaways

17. APPENDIX 1: LIST OF ADDITIONAL SUPPLY CHAIN MANAGEMENT SOFTWARE SOLUTIONS

18. APPENDIX 2: TABULATED DATA

19. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/kw1hkc

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Here is the original post:
Cell and Advanced Therapies Supply Chain Management Industry Report, 2019-2030 - GlobeNewswire

Read More...

Regenerative Medicine Market Segmentation, Top Companies, Applications, Comprehensive Research Report and Forecast to 2026 – Market Research Sheets

Monday, December 30th, 2019

The recent report added by Verified Market Research gives a detailed account of the drivers and restraints in the Global Regenerative Medicine market. The research report, titled [Global Regenerative Medicine Market Size and Forecast to 2026] presents a comprehensive take on the overall market. Analysts have carefully evaluated the milestones achieved by the global Regenerative Medicine market and the current trends that are likely to shape its future. Primary and secondary research methodologies have been used to put together an exhaustive report on the subject. Analysts have offered unbiased outlook on the global Regenerative Medicine market to guide clients toward a well-informed business decision.

Global Regenerative Medicine Market was valued at USD 19.10 Billion in 2018 and is expected to witness a growth of 22.72% from 2019-2026 and reach USD 98.10 Billion by 2026.

The comprehensive research report has used Porters five forces analysis and SWOT analysis to give the readers a fair idea of the direction the global Regenerative Medicine market is expected to take. The Porters five forces analysis highlights the intensity of the competitive rivalry while the SWOT analysis focuses on explaining strengths, weaknesses, opportunities, and threats present in the global Regenerative Medicine market. The research report gives an in-depth explanation of the trends and consumer behavior pattern that are likely to govern the evolution of the global Regenerative Medicine market.

The following Companies as the Key Players in the Global Regenerative Medicine Market Research Report:

Regions Covered in the Global Regenerative Medicine Market:

Europe (Germany, Russia, UK, Italy, Turkey, France, etc.)

The Middle East and Africa (GCC Countries and Egypt)

North America (United States, Mexico, and Canada)

South America (Brazil etc.)

Asia-Pacific (China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The scope of the Report:

The research report on global Regenerative Medicine market includes segmentation on the basis of technology, application, end users, and region. Each segmentation is a chapter, which explains relevant components. The chapters include graphs to explain the year-on-year progress and the segment-specific drivers and restraints. In addition, the report also provides the government outlooks within the regional markets that are impacting the global Regenerative Medicine market.

Lastly, Verified Market Researchs report on Regenerative Medicine market includes a detailed chapter on the company profiles. This chapter studies the key players in the global Regenerative Medicine market. It mentions the key products and services of the companies along with an explanation of the strategic initiatives. An overall analysis of the strategic initiatives of the companies indicates the trends they are likely to follow, their research and development statuses, and their financial outlooks. The report intends to give the readers a comprehensive point of view about the direction the global Regenerative Medicine market is expected to take.

Ask for Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7157&utm_source=MRS&utm_medium=005

Table of Content

1 Introduction of Regenerative Medicine Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Regenerative Medicine Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Regenerative Medicine Market, By Deployment Model

5.1 Overview

6 Regenerative Medicine Market, By Solution

6.1 Overview

7 Regenerative Medicine Market, By Vertical

7.1 Overview

8 Regenerative Medicine Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Regenerative Medicine Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Customization of Report @ https://www.verifiedmarketresearch.com/product/global-regenerative-medicine-market/?utm_source=MRS&utm_medium=005

We also offer customization on reports based on specific client requirement:

1- Free country level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any market players.

3- Free 40 analyst hours to cover any other data points

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

This post was originally published on Market Research Sheets

See more here:
Regenerative Medicine Market Segmentation, Top Companies, Applications, Comprehensive Research Report and Forecast to 2026 - Market Research Sheets

Read More...

Doctors goal: End the wait for lung transplants – Jacksonville Daily Record

Monday, December 30th, 2019

As a critical care resident from Peru studying at Saint Louis University, the process of a lung transplant caught Dr. Jorge Malleas attention.

It was very interesting to me to see how you could actually change one persons lungs for another persons lungs and then make it work, said Mallea, medical director of Mayo Clinics lung restoration facility.

It was very intense, very labor demanding, intellectually, very challenging, he said.

Mallea went on to complete his fellowship in pulmonary medicine at Saint Louis University in St. Louis, Missouri.

As he was looking for work, a mentor from his residency, Dr. Cesar Keller, recruited him to join the lung transplant team at Mayo Clinic.

Two other doctors he knew from St. Louis already were at Mayo Clinic in Jacksonville, so Mallea joined the hospital in 2003.

In 2015, Mayo Clinic announced it would partner with United Therapeutics to develop a lung restoration center on its Jacksonville campus.

The form of regenerative medicine is designed to take donor lungs thatpreviously would have been unusable and turn them into viable transplant organs.

The center is on the first floor of the new Discovery and Innovation building on Mayo Clinics campus.

In August, Mallea became medical director of the facility. He believes the technology can change the way lung transplants are done.

The ex-vivo lung perfusion technology, which is used in the facility, allows for the lung restoration team to spend more time with donor lungs, which would help make more lungs available for transplant.

Mallea said the technology can make the lungs treated in the Jacksonville facility better than the standard lung, and last longer than the typical lung transplant.

He wants to save the nearly 400 people who die annually waiting for a lung transplant.

The goal is to chop that number from 400 to zero, Mallea said.

So far, only trials have been completed in the Mayo Clinic facility, which opened in August. When it receives FDA approval, which likely will be in January, the facility will have the capacity to treat nearly 900 lungs each year.

Aside from serving as medical director of the facility, Mallea works as a pulmonologist, seeing patients suffering from COPD or emphysema on campus.

He said those patients, given the nature of their disease and chance of mortality within the next year, often are low on the list to receive a transplant.

Part of his work at Mayo Clinic is trying to find solutions for those patients. Hes working on developing a trial to treat COPD patients with mesenchymal stem cells, but its in the early stages, he said.

Mallea said he and the United Therapeutics team also hope to be able to regenerate lungs using biomaterials or stem cells in the future, which would create more ways to increase the lung donor pool.

Sometimes its looking into the future and it looks like science fiction, Mallea said. But it really is exciting, the things that we can do, or the things that were hoping to do soon.

Working on the lung transplant and now lung restoration teams has been rewarding, Mallea said. Hes seen lung restoration in action at United Therapeutics Silver Spring, Maryland, facility, which performs the procedures.

Sometimes lungs will come into the facility, and its unclear if they will work for a transplant. After inspection and by tweaking a few things, those lungs can then be suitable, he said.

You can see the difference that having them in the facility can make, he said. So thats definitely a satisfaction of being part of that team, being able to know that another persons getting a second chance of life because theyre receiving lungs that are going to save their lives.

Mallea considers himself lucky to be in a situation where I can be part of developing, discovering and hopefully transforming the future with a great team.

See more here:
Doctors goal: End the wait for lung transplants - Jacksonville Daily Record

Read More...

FAU Athletics Receives $5 Million Sponsorship from Roof Claim to Name FAU Arena – The Boca Raton Tribune

Monday, December 30th, 2019

Brian Wedding

Boca Raton, FL The Florida Atlantic University Athletic Department has partnered with Brian Wedding and RoofClaim.com on a $5 million, 10-year sponsorship to name the RoofClaim.com Arena, home of the FAU mens and womens basketball and volleyball teams.

We are tremendously excited to partner with Brian Wedding and RoofClaim.com, saidBrian White,vice president and director of athletics. This partnership is transformational for our student-athletes and fans, as well as the community. We are thrilled about the opportunities provided to FAU and our athletics department from this investment.

Wedding is the founder/CEO of RoofClaim.com, a company he has aligned with several reputable and charitable companies and organizations though corporate partnerships. RoofClaim.com is a technology service company specializing in the diagnosing and processing of shingle and tile roof replacement insurance claims though the use of cutting-edge technology, and industry leading processes. The company is recognized nationally for its services and is also a member of the National Roofing Contractors Association and the National Association of Home Builders. RoofClaim.com is a subsidiary ofJasper Inc.

I am very excited about the growth and vision of Florida Atlantic University, under the direction of President Kelly and Director of Athletics Brian White, said Wedding. There is a lot of synergy between FAU and RoofClaim.com. We are both working to help those in the South Florida region, as well as expand the student and fan experience. I look forward to raising a championship trophy with FAU one day.

Florida Atlantic University Athletics:

FAU Athletics is comprised of 21 intercollegiate teams involving 450 student athletes that compete in baseball, basketball, cross country,football, golf, soccer, softball, swimming and diving, tennis, indoor and outdoor track, volleyball, beach volleyball, cheer and dance. The Owls are a NCAA Division I-A (FBS) institution and compete in Conference USA and the Coastal Collegiate Sports Association (CCSA) (Beach Volleyball, Mens Swimming). The Owls have been playing football since 2001 and have captured two bowl games. The dance team finished its 2014 season No. 8, nationally. FAU Cheer won a national championship in 2016.

About Florida Atlantic University:

Florida Atlantic University, established in 1961, officially opened its doors in 1964 as the fifth public university in Florida. Today, the University, with an annual economic impact of $6.3 billion, serves more than 30,000 undergraduate and graduate students at sites throughout its six county service region in southeast Florida. FAUs world-class teaching and research faculty serves students through 10 colleges: the Dorothy F. Schmidt College of Arts and Letters, the College of Business, the College for Design and Social Inquiry, the College of Education, the College of Engineering and Computer Science, the Graduate College, the Harriet L. Wilkes Honors College, the Charles E. Schmidt College of Medicine, the Christine E. Lynn College of Nursing and the Charles E. Schmidt College of Science. FAU is ranked as a High Research Activity institution by the Carnegie Foundation for the Advancement of Teaching. The University is placing special focus on the rapid development of critical areas that form the basis of its strategic plan: Healthy aging, biotech, coastal and marine issues, neuroscience, regenerative medicine, informatics, lifespan and the environment. These areas provide opportunities for faculty and students to build upon FAUs existing strengths in research and scholarship. For more information, visitfau.edu.

Arena

Link:
FAU Athletics Receives $5 Million Sponsorship from Roof Claim to Name FAU Arena - The Boca Raton Tribune

Read More...

Page 29«..1020..28293031..4050..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick